Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17216168 | 0.82 | IDO1 (0.53) | IDO1MAOBTAAR1HTT | |
| SCHEMBL17219621 | 0.81 | IDO1 (0.42) | IDO1MAOBKMT2ATAAR1ALDH1A1 | |
| SCHEMBL17219762 | 0.81 | PDE2A (0.40) | ALDH1A1 | |
| SCHEMBL17217363 | 0.80 | IDO1 (0.50) | IDO1MAOBKMT2ATAAR1KDM4E | |
| SCHEMBL17218301 | 0.80 | AGXT (0.44) | IDO1MAOBTAAR1ALDH1A1NPC1 | |
| SCHEMBL17216686 | 0.80 | TAAR1 (0.36) | IDO1KMT2ATAAR1ALDH1A1NPC1 | |
| SCHEMBL17218435 | 0.79 | IDO1 (0.49) | IDO1MAOBKMT2ATAAR1ALDH1A1 | |
| SCHEMBL17219416 | 0.79 | IDO1 (0.37) | IDO1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL20732769 | 0.78 | L3MBTL1 (0.49) | IDO1MAOBKMT2AALDH1A1NPC1 | |
| SCHEMBL17215939 | 0.78 | L3MBTL1 (0.49) | IDO1MAOBKMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940012-B1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL CO (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-9560850-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2940012-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | Sumitomo Chemical Company Limited (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | RTN3, CYP51A1, TCOF1 | IDO1 2882/4885MAOB 3611/4885KMT2A 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.